文献速递泌尿男性生殖肿瘤

免疫检查点抑制剂在晚期肾细胞癌中的应用:迄今经验与未来方向

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
PubMed 文献 · Ann Oncol · 2017-01-01

本文综述了免疫检查点抑制剂治疗晚期肾细胞癌的现有证据。程序性死亡受体1(PD-1)抑制剂纳武利尤单抗基于总生存优于哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂依维莫司,已在美欧获批用于既往治疗过的晚期肾细胞癌患者。其他检查点抑制剂及联合方案仍在临床开发中。

要点

  • 纳武利尤单抗基于总生存优于依维莫司,在美欧获批用于既往治疗过的晚期肾细胞癌。
  • 靶向细胞毒性T淋巴细胞相关抗原4(CTLA-4)的伊匹木单抗联合方案及程序性死亡配体1(PD-L1)抑制剂阿替利珠单抗在晚期肾细胞癌中处于不同临床开发阶段。
  • 综述涵盖非常规缓解的频率与管理、免疫相关不良事件管理及未来方向。

核心结论

  • 免疫检查点抑制剂已改变晚期肾细胞癌治疗格局,纳武利尤单抗基于总生存优于依维莫司获批用于既往治疗患者,其他药物仍在开发中。

研究设计与样本

  • 综述总结免疫检查点抑制剂治疗晚期肾细胞癌的现有临床证据,涵盖非常规缓解、免疫相关不良事件管理及未来方向。

主要发现

  • 靶向程序性死亡受体1(PD-1)和细胞毒性T淋巴细胞相关抗原4(CTLA-4)通路的药物在转移性黑色素瘤、非小细胞肺癌、晚期肾细胞癌、晚期头颈部鳞状细胞癌、尿路上皮癌和霍奇金淋巴瘤中显示临床疗效并获监管批准。
  • 在晚期肾细胞癌中,程序性死亡受体1(PD-1)抑制剂纳武利尤单抗基于总生存优于哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂依维莫司,在美国和欧洲获批用于既往接受过治疗的患者。
  • 其他检查点抑制剂包括细胞毒性T淋巴细胞相关抗原4(CTLA-4)抑制剂伊匹木单抗联合多种药物及程序性死亡配体1(PD-L1)抑制剂阿替利珠单抗,在晚期肾细胞癌中处于不同临床开发阶段。

关键数值与推荐

  • 纳武利尤单抗在晚期肾细胞癌中基于总生存优于依维莫司,在美欧获批用于既往治疗患者。

临床怎么用

  • 纳武利尤单抗可用于既往治疗过的晚期肾细胞癌患者。
  • 需关注非常规缓解的频率与管理及免疫相关不良事件的管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, there has been dramatic expansion of the treatment armamentarium for patients with advanced renal cell carcinoma (aRCC), including drugs targeting vascular endothelial growth factor and mammalian target of rapamycin (mTOR) pathways. Despite these advances, patient outcomes remain suboptimal, underscoring the need for therapeutic interventions with novel mechanisms of action. The advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment landscape for several solid malignancies. Specifically, drugs targeting the programmed death 1 (PD-1) and cytotoxic T-lymphocyte associated antigen (CTLA-4) pathways have demonstrated considerable clinical efficacy and gained regulatory approval as single-agent or combination therapy for the treatment of patients with metastatic melanoma, non-small cell lung cancer, aRCC, advanced squamous cell carcinoma of the head and neck, urothelial cancer and Hodgkin lymphoma. In aRCC, the PD-1 inhibitor nivolumab was approved in both the United States and Europe for the treatment of patients who have received prior therapy, based on improved overall survival compared with the mTOR inhibitor everolimus. Other checkpoint inhibitors, including the CTLA-4 inhibitor ipilimumab in combination with several agents, and the PD-L1 inhibitor atezolizumab, are in various stages of clinical development in patients with aRCC. In this review, current evidence related to the clinical use of checkpoint inhibitors for the treatment of patients with aRCC is discussed, including information on the frequency and management of unconventional responses and the management of immune-related adverse events. In addition, perspectives on the future use of checkpoint inhibitors are discussed, including the potential value of treatment beyond progression, the potential use in earlier lines of care or in combination with other agents, and the identification of biomarkers to guide patient selection and enable individualization of therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Atkins MB, Clark JI, Quinn DI, et al. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. 2017. PMID: 28383639. doi:10.1093/annonc/mdx151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。